Selected research
Industry Growth & Trends
Global Favipiravir Industry Growth and Trends Forecast to 2032
Market perspective
The global Favipiravir market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Favipiravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Favipiravir include ChemRar Group, Cipla, Dr. Reddy, Fujifilm, Glenmark, Lupin, R-Pharma, Sun Pharma and Hisun Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Favipiravir market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Favipiravir market size, estimates, and forecasts are presented in terms of sales volume (K Pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Favipiravir market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Favipiravir.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Favipiravir market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Favipiravir Market by Company
ChemRar Group
Cipla
Dr. Reddy
Fujifilm
Glenmark
Lupin
R-Pharma
Sun Pharma
Hisun Pharm
Favipiravir Segment by Type
Brand Drug
Generic Drug
Favipiravir Segment by Application
Influenza Viruses
COVID-19
Others
Favipiravir Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Favipiravir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Favipiravir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Favipiravir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Favipiravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Brand Drug
- Generic Drug
Applications
- Influenza Viruses
- COVID-19
- Others
Companies covered
- ChemRar Group
- Cipla
- Dr. Reddy
- Fujifilm
- Glenmark
- Lupin
- R-Pharma
- Sun Pharma
- Hisun Pharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Favipiravir Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Favipiravir Sales Estimates and Forecasts (2021-2032)
- 1.3 Favipiravir Market by Type
- 1.3.1 Brand Drug
- 1.3.2 Generic Drug
- 1.4 Global Favipiravir Market Size by Type
- 1.4.1 Global Favipiravir Market Size Overview by Type (2021-2032)
- 1.4.2 Global Favipiravir Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Favipiravir Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Favipiravir Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Favipiravir Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Favipiravir Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Favipiravir Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Favipiravir Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Favipiravir Industry Trends
- 2.2 Favipiravir Industry Drivers
- 2.3 Favipiravir Industry Opportunities and Challenges
- 2.4 Favipiravir Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Favipiravir Revenue (2021-2026)
- 3.2 Global Top Players by Favipiravir Sales (2021-2026)
- 3.3 Global Top Players by Favipiravir Price (2021-2026)
- 3.4 Global Favipiravir Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Favipiravir Major Company Production Sites & Headquarters
- 3.6 Global Favipiravir Company, Product Type & Application
- 3.7 Global Favipiravir Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Favipiravir Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Favipiravir Players Market Share by Revenue in 2025
- 3.8.3 2025 Favipiravir Tier 1, Tier 2, and Tier 3
4 Favipiravir Regional Status and Outlook
- 4.1 Global Favipiravir Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Favipiravir Historic Market Size by Region
- 4.2.1 Global Favipiravir Sales in Volume by Region (2021-2026)
- 4.2.2 Global Favipiravir Sales in Value by Region (2021-2026)
- 4.2.3 Global Favipiravir Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Favipiravir Forecasted Market Size by Region
- 4.3.1 Global Favipiravir Sales in Volume by Region (2027-2032)
- 4.3.2 Global Favipiravir Sales in Value by Region (2027-2032)
- 4.3.3 Global Favipiravir Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Favipiravir by Application
- 5.1 Favipiravir Market by Application
- 5.1.1 Influenza Viruses
- 5.1.2 COVID-19
- 5.1.3 Others
- 5.2 Global Favipiravir Market Size by Application
- 5.2.1 Global Favipiravir Market Size Overview by Application (2021-2032)
- 5.2.2 Global Favipiravir Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Favipiravir Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Favipiravir Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Favipiravir Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Favipiravir Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Favipiravir Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Favipiravir Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 ChemRar Group
- 6.1.1 ChemRar Group Company Information
- 6.1.2 ChemRar Group Business Overview
- 6.1.3 ChemRar Group Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 ChemRar Group Favipiravir Product Portfolio
- 6.1.5 ChemRar Group Recent Developments
- 6.2 Cipla
- 6.2.1 Cipla Company Information
- 6.2.2 Cipla Business Overview
- 6.2.3 Cipla Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Cipla Favipiravir Product Portfolio
- 6.2.5 Cipla Recent Developments
- 6.3 Dr. Reddy
- 6.3.1 Dr. Reddy Company Information
- 6.3.2 Dr. Reddy Business Overview
- 6.3.3 Dr. Reddy Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Dr. Reddy Favipiravir Product Portfolio
- 6.3.5 Dr. Reddy Recent Developments
- 6.4 Fujifilm
- 6.4.1 Fujifilm Company Information
- 6.4.2 Fujifilm Business Overview
- 6.4.3 Fujifilm Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Fujifilm Favipiravir Product Portfolio
- 6.4.5 Fujifilm Recent Developments
- 6.5 Glenmark
- 6.5.1 Glenmark Company Information
- 6.5.2 Glenmark Business Overview
- 6.5.3 Glenmark Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Glenmark Favipiravir Product Portfolio
- 6.5.5 Glenmark Recent Developments
- 6.6 Lupin
- 6.6.1 Lupin Company Information
- 6.6.2 Lupin Business Overview
- 6.6.3 Lupin Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Lupin Favipiravir Product Portfolio
- 6.6.5 Lupin Recent Developments
- 6.7 R-Pharma
- 6.7.1 R-Pharma Company Information
- 6.7.2 R-Pharma Business Overview
- 6.7.3 R-Pharma Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 R-Pharma Favipiravir Product Portfolio
- 6.7.5 R-Pharma Recent Developments
- 6.8 Sun Pharma
- 6.8.1 Sun Pharma Company Information
- 6.8.2 Sun Pharma Business Overview
- 6.8.3 Sun Pharma Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Sun Pharma Favipiravir Product Portfolio
- 6.8.5 Sun Pharma Recent Developments
- 6.9 Hisun Pharm
- 6.9.1 Hisun Pharm Company Information
- 6.9.2 Hisun Pharm Business Overview
- 6.9.3 Hisun Pharm Favipiravir Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Hisun Pharm Favipiravir Product Portfolio
- 6.9.5 Hisun Pharm Recent Developments
7 North America by Country
- 7.1 North America Favipiravir Sales by Country
- 7.1.1 North America Favipiravir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Favipiravir Sales by Country (2021-2026)
- 7.1.3 North America Favipiravir Sales Forecast by Country (2027-2032)
- 7.2 North America Favipiravir Market Size by Country
- 7.2.1 North America Favipiravir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Favipiravir Market Size by Country (2021-2026)
- 7.2.3 North America Favipiravir Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Favipiravir Sales by Country
- 8.1.1 Europe Favipiravir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Favipiravir Sales by Country (2021-2026)
- 8.1.3 Europe Favipiravir Sales Forecast by Country (2027-2032)
- 8.2 Europe Favipiravir Market Size by Country
- 8.2.1 Europe Favipiravir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Favipiravir Market Size by Country (2021-2026)
- 8.2.3 Europe Favipiravir Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Favipiravir Sales by Country
- 9.1.1 Asia-Pacific Favipiravir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Favipiravir Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Favipiravir Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Favipiravir Market Size by Country
- 9.2.1 Asia-Pacific Favipiravir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Favipiravir Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Favipiravir Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Favipiravir Sales by Country
- 10.1.1 South America Favipiravir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Favipiravir Sales by Country (2021-2026)
- 10.1.3 South America Favipiravir Sales Forecast by Country (2027-2032)
- 10.2 South America Favipiravir Market Size by Country
- 10.2.1 South America Favipiravir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Favipiravir Market Size by Country (2021-2026)
- 10.2.3 South America Favipiravir Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Favipiravir Sales by Country
- 11.1.1 Middle East and Africa Favipiravir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Favipiravir Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Favipiravir Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Favipiravir Market Size by Country
- 11.2.1 Middle East and Africa Favipiravir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Favipiravir Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Favipiravir Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Favipiravir Value Chain Analysis
- 12.1.1 Favipiravir Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Favipiravir Production Mode & Process
- 12.2 Favipiravir Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Favipiravir Distributors
- 12.2.3 Favipiravir Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst